2024
Phylogeographic Analysis of Mycobacterium kansasii Isolates from Patients with M. kansasii Lung Disease in Industrialized City, Taiwan - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC
Tobias Cudahy P, Liu P, Warren J, Sobkowiak B, Yang C, Ioerger T, Wu C, Lu P, Wang J, Chang H, Huang H, Cohen T, Lin H. Phylogeographic Analysis of Mycobacterium kansasii Isolates from Patients with M. kansasii Lung Disease in Industrialized City, Taiwan - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 1562-1570. PMID: 39043390, PMCID: PMC11286038, DOI: 10.3201/eid3008.240021.Peer-Reviewed Original ResearchConceptsM. kansasii lung diseaseM. kansasii pulmonary diseasePulmonary diseaseM. kansasii isolatesSputum mycobacterial cultureWhole-genome sequencingEvaluate risk factorsPhylogeographic analysisAge of participantsGenetic relatednessEnvironmental acquisitionLung diseaseMycobacterial cultureOdds ratioRisk factorsM. kansasiiPatientsDiseasePlantsEnvironmental transmissionIsolatesPark plantingsCDCRisk
2022
Phylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis
Yang C, Sobkowiak B, Naidu V, Codreanu A, Ciobanu N, Gunasekera KS, Chitwood MH, Alexandru S, Bivol S, Russi M, Havumaki J, Cudahy P, Fosburgh H, Allender CJ, Centner H, Engelthaler DM, Menzies NA, Warren JL, Crudu V, Colijn C, Cohen T. Phylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis. PLOS Medicine 2022, 19: e1003933. PMID: 35192619, PMCID: PMC8903246, DOI: 10.1371/journal.pmed.1003933.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisDrug-resistant M. tuberculosisM. tuberculosis strainsPutative transmission clustersM. tuberculosisTransmission clustersMultidrug-resistant M. tuberculosis strainsTuberculosis strainsMultiple M. tuberculosis strainsCulture-positive TB casesLocal transmissionMDR-TB epidemicDrug-susceptible tuberculosisDrug resistance mutationsDrug resistance profilesUrgency of interventionTB casesDemographic dataNew casesTuberculosisInadequate treatmentNatural historyResistance mutationsBeijing lineageMycobacterium tuberculosis
2020
Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study
Cudahy PGT, Wilson D, Cohen T. Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study. BMC Infectious Diseases 2020, 20: 789. PMID: 33097000, PMCID: PMC7585300, DOI: 10.1186/s12879-020-05515-4.Peer-Reviewed Original ResearchConceptsM. tuberculosis infectionRecurrent tuberculosisSuccessful treatmentTuberculosis recurrenceHazard ratioSmear gradeTuberculosis infectionRisk factorsSmear-positive pulmonary tuberculosisCox proportional hazards modelSputum smear gradeRepetitive unit-variable number tandem repeat (MIRU-VNTR) typingHigh-burden settingsRisk of recurrenceProportional hazards modelSuccessful treatment completionRecurrent diseaseCohort studyPulmonary tuberculosisBurden settingsClinical presentationRecurrent episodesInitial episodeNumber tandem repeat typingTreatment completion
2018
Spatially targeted screening to reduce tuberculosis transmission in high-incidence settings
Cudahy PGT, Andrews JR, Bilinski A, Dowdy DW, Mathema B, Menzies NA, Salomon JA, Shrestha S, Cohen T. Spatially targeted screening to reduce tuberculosis transmission in high-incidence settings. The Lancet Infectious Diseases 2018, 19: e89-e95. PMID: 30554997, PMCID: PMC6401264, DOI: 10.1016/s1473-3099(18)30443-2.Peer-Reviewed Original ResearchConceptsTuberculosis incidenceLow tuberculosis incidence settingsActive case-finding strategyHigh tuberculosis (TB) incidence countriesCase-finding strategyTuberculosis control strategiesHigh-incidence settingsInfectious causesIncidence settingsIncidence countriesTuberculosis transmissionTreatment outcomesActive screeningOnward transmissionSystematic reviewInfectious individualsInfectious periodTuberculosisIncidenceDeathCauseProximal causeHIVMixed resultsMortalityTrends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis.
Cudahy PGT, Warren JL, Cohen T, Wilson D. Trends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis. American Journal Of Tropical Medicine And Hygiene 2018, 99: 1336-1341. PMID: 30226135, PMCID: PMC6221241, DOI: 10.4269/ajtmh.18-0322.Peer-Reviewed Original ResearchConceptsC-reactive proteinMulti-drug resistant tuberculosisD-dimerMedian C-reactive proteinSerum C-reactive proteinHigher baseline fibrinogenMDR-TB therapyHIV-positive adultsDrug-resistant tuberculosisHIV-positive participantsHigher CRP concentrationsEarly treatment modificationBaseline fibrinogenTreatment initiationResistant tuberculosisCRP concentrationsTreatment modificationTreatment outcomesTreatment responseHigh riskHigh mortalityNormal levelsOlder ageEarly responseFibrinogenEvaluation of Tuberculosis Treatment Response With Serial C-Reactive Protein Measurements
Wilson D, Moosa MS, Cohen T, Cudahy P, Aldous C, Maartens G. Evaluation of Tuberculosis Treatment Response With Serial C-Reactive Protein Measurements. Open Forum Infectious Diseases 2018, 5: ofy253. PMID: 30474046, PMCID: PMC6240901, DOI: 10.1093/ofid/ofy253.Peer-Reviewed Original ResearchC-reactive proteinTuberculosis groupAntituberculosis therapyWeek 2Serial C-reactive protein measurementsC-reactive protein measurementTuberculosis treatment responseNegative sputum smearsSmear-negative patientsSmear-negative tuberculosisSymptoms of tuberculosisMedian weight gainCohort of adultsNegative predictive valueAntituberculosis treatmentCRP reductionHIV testingHIV prevalenceAdverse outcomesSputum smearHemoglobin increaseSerial changesWeek 8Treatment responseBaseline values
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply